 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||
5 February 2008 | Volume 148 Issue 3 | Pages 234-238
Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target vessel revascularization compared with bare-metal stents. However, the safety of drug-eluting stents has been called into question because of an apparent increase in late stent thrombosis, a frequently fatal event. A substantial body of research has focused on determining the magnitude of these competing events, often reaching contradictory results even with analyses of the same data. Although larger, adequately powered, randomized trials are needed to fully assess the net clinical effects of drug-eluting stents compared with bare-metal stents, the evidence seems to suggest that the net clinical benefit of drug-eluting stents may outweigh their risks. The evidence is clearer that premature discontinuation of antiplatelet therapy is an important trigger for stent thrombosis; therefore, patients who are candidates for implantation of drug-eluting stents should be screened for their ability to receive and tolerate uninterrupted antiplatelet therapy longer than is necessary with bare-metal stents. The evidence suggests that drug-eluting stents relieve obstructive coronary artery disease, provide durable mechanical results, and do more good than harm, but all patients also should be given antiplatelet and other optimal medical therapies to achieve the best outcomes.
Author and Article Information
From Stony Brook University Medical Center, Stony Brook, and Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York.
Potential Financial Conflicts of Interest: Consultancies: A. Kirtane (Medtronic Vascular). Honoraria: A. Kirtane (Boston Scientific).
Requests for Single Reprints: Allen Jeremias, MD, MSc, Division of Cardiovascular Medicine, Stony Brook University Medical Center, Health Sciences Center T16-080, Stony Brook, NY 11794; e-mail, allen.jeremias{at}stonybrook.edu.
Current Author Addresses: Dr. Jeremias: Division of Cardiovascular Medicine, Stony Brook University Medical Center, Health Sciences Center T16-080, Stony Brook, NY 11794.
Dr. Kirtane: Division of Cardiovascular Medicine, New York-Presbyterian Hospital, 161 Fort Washington Avenue, New York, NY 10032. PERSPECTIVE
Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J. Kirtane, A. Gupta, S. Iyengar, J. W. Moses, M. B. Leon, R. Applegate, B. Brodie, E. Hannan, K. Harjai, L. O. Jensen, et al. Safety and Efficacy of Drug-Eluting and Bare Metal Stents: Comprehensive Meta-Analysis of Randomized Trials and Observational Studies Circulation, June 30, 2009; 119(25): 3198 - 3206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Douglas, J. M. Brennan, K. J. Anstrom, A. Sedrakyan, E. L. Eisenstein, G. Haque, D. Dai, D. F. Kong, B. Hammill, L. Curtis, et al. Clinical Effectiveness of Coronary Stents in Elderly Persons: Results From 262,700 Medicare Patients in the American College of Cardiology-National Cardiovascular Data Registry J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1629 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Mark Interpreting the Music of Drug-Eluting Stents: Halcyon Song or Albatross Dirge? J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1854 - 1856. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Di Mario and P. Barlis Optical Coherence Tomography: A New Tool to Detect Tissue Coverage in Drug-Eluting Stents J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 174 - 175. [Full Text] [PDF]
|
|
Read all Rapid Responses
